MaxCyte, Inc. Highlights High Titer Protein Production Using Biologically Relevant Cells in an Upcoming Educational Webinar Presentation
12/11/2012 11:05:05 AM
GAITHERSBURG, Md.--(BUSINESS WIRE)--MaxCyte, Inc., the pioneer in scalable, high performance transient transfection systems, is hosting an educational webinar entitled Transient Transfection of Biologically Relevant Cells: CEVEC CAP-T™ Technology for High Yield Expression of Proteins in Human Derived Cells on Wednesday, December 12, 2012, from 11:00 AM – 12:00 PM EST. This scientific program will focus on the use of MaxCyte’s proprietary large scale transfection platform in combination with Cevec’s CAP-T technology for the production of proteins and antibodies with authentic human glycosylation and sialylation. Technical presentations will be given by Dr. James Brady, Director of Technical Applications at MaxCyte, and Dr. Hartmut Tintrup, VP Business Development & Licensing at Cevec Pharmaceuticals.